Artivion Inc
NYSE: AORT · HEALTHCARE · MEDICAL DEVICES
Updated 2026-04-29
Artivion Inc (AORT) Stock Valuation Analysis
Fair value estimate, historical valuation range, and quality signals for AORT.
Current price exceeds what fundamentals support. Risk/reward skewed unfavorably.
AORT historical valuation range
Where current P/E sits in AORT's own 5Y range.
AORT intrinsic value (DCF)
DCF-based fair value estimate vs current market price.
Intrinsic value calculated using discounted cash flow (DCF) model based on projected free cash flows, discount rate, and terminal growth assumptions. A positive margin of safety indicates the current price is below estimated fair value, providing a cushion against estimation error.
AORT valuation signals
Quick-read green flags, caution flags, and risks based on current metrics.
P/E Ratio — History
Current: 164.95x
P/S Ratio — History
Current: 3.81x
Is AORT overvalued in 2026?
Artivion Inc (AORT) currently trades at $34.64 per share with a market capitalization of $1,679,901,000.00. Based on our multi-factor framework, the stock appears richly valued with a Smart Value Score of 39/100. This score blends growth quality, financial health, and price attractiveness into a single institutional-grade read.
The stock trades at a P/E ratio of 164.9x, below its 5-year median of 179.4x. The PEG ratio of 181.50 indicates the price has run ahead of the underlying growth rate.
Looking at its own history, AORT is currently trading cheaper than 83% of the last 5Y on P/E. This places it in the 17th percentile of its historical range, a level that has historically coincided with attractive entry points.
Our discounted cash flow model estimates AORT's intrinsic value at $35.30 per share, against the current market price of $34.64. This implies a premium to fair value of -13.60%. The current price sits well above what projected cash flows justify, implying investors are paying for growth that has not yet materialized.
Financial quality is a concern. The Piotroski F-Score of 0/9 flags weakening fundamentals that deserve closer scrutiny before the valuation case can be fully trusted.
Bottom line: AORT appears richly valued on our framework, with a Smart Value Score of 39/100. At current levels the risk/reward is skewed against the buyer. A materially lower price or significant operational improvement would be needed to change the picture.
Frequently asked questions
Is AORT overvalued in 2026?
Based on a Smart Value Score of 39/100, AORT appears overvalued. Current price exceeds what fundamentals currently justify.
What is AORT's fair value?
Our DCF model estimates AORT's intrinsic value at $35.30 per share, versus the current price of $34.64. This produces a margin of safety of -13.60%.
What P/E ratio does AORT trade at?
AORT trades at a P/E of 164.9x on trailing twelve-month earnings, compared to its 5-year median of 179.4x.
Is AORT a buy based on valuation?
WallStSmart does not issue buy or sell recommendations. Our Smart Value Score of 39/100 reflects the combined read on growth, quality, and price. The profile skews cautious. Consider waiting for a better price or clearer operational improvement.
How does AORT's valuation compare to its history?
On P/E, AORT currently sits in the 17th percentile of its own 5Y range. That is historically cheap relative to where it has traded over the period.
What is AORT's Smart Value Score?
AORT's Smart Value Score is 39/100. The Smart Value Score is a proprietary WallStSmart metric blending growth quality, financial health, and valuation attractiveness into a single 0-100 read. Scores above 75 are rare and indicate strong multi-factor alignment.